A Phase 2 interventional study of Venetoclax and Bendamustine in Follicular Lymphoma, sponsored by Hoffmann-La Roche. Completed at 71 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-05.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing venetoclax in Lymphoma, Follicular — 1 open to participants now, 5 under way, none of them phase 3. venetoclax · Lymphoma, Follicular.
Among the 14 studies testing venetoclax in Lymphoma, Follicular, this one has the largest enrollment, is the only one that started in 2014, is one of 6 in phase 2, and was the 1st registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →1 of the 14 studies testing venetoclax in Lymphoma, Follicular is open now, in 1 country. Recruiting first, the newest first:
Chinese PLA General Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 9
First in 2014; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 25 across the 14 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
22 studies in Lymphoma, Follicular by Hoffmann-La Roche: none open now, 2 under way, 1 of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 22 studies in Lymphoma, Follicular by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 2, and was the 7th registered.
Hoffmann-La Roche’s Lymphoma, Follicular studies by the year they started, since 2004.
3 of the studies testing venetoclax in Lymphoma, Follicular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03980171Peter MacCallum Cancer Centre, AustraliaStudy of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma | 2026-11 |
| NCT06471738Chinese PLA General HospitalCombination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | 2026-12-30 |
| NCT04450173University of California, DavisObinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing venetoclax in Lymphoma, Follicular, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 22 in Lymphoma, Follicular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, international, multicenter study will investigate the safety and efficacy of venetoclax (GDC-0199) in combination with bendamustine plus rituximab (venetoclax + BR) compared with BR alone in participants with relapsed and refractory fNHL, comparing two chemotherapy-containing regimens (Chemotherapy-Containing Cohort). In addition, an exploratory analysis of the safety and efficacy of venetoclax in combination with rituximab (venetoclax + rituximab), a chemotherapy-free regimen, will be performed (Chemotherapy-Free Cohort). Assignment to the Chemotherapy-Containing or Chemotherapy-Free Cohort will be decided at the discretion of the Investigator, unless one of the cohorts is not open to enrollment; in which case, participants may be enrolled only to the open cohort. The first 6 participants enrolled in the Chemotherapy-Containing Cohort (or more if required) will comprise the Safety Run-In group for Treatment Arm B, dosing venetoclax at 600 milligrams (mg) in combination with BR. Once a dose has been chosen from the Safety Run-In Period, randomization to the two treatment arms of the Chemotherapy-Containing Cohort (Arms B and C) will begin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive venetoclax no more than 600 milligrams (mg) orally once daily continuously along with rituximab 375 milligrams per square meter (mg/m\^2) intravenous (IV) infusion on Day 1 of 28-day cycle and bendamustine 90 mg/m\^2 IV infusion on Days 1 and 2 of the 28-day cycle. Safety run-in will continue until first 9 participants complete the safety observation window of 28 days. Participants will continue receiving the same treatment as decided for Arm B.
Drug: Venetoclax · Drug: Bendamustine · Drug: Rituximab
Participants will receive venetoclax 800 mg orally once daily for 1 year along with rituximab 375 mg/m\^2 IV infusion on Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, 10, and 12. Each cycle will be of 28 days.
Drug: Venetoclax · Drug: Rituximab
Participants will receive venetoclax at doses decided from safety run-in orally once daily continuously for 1 year along with rituximab 375 mg/m\^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m\^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
Drug: Venetoclax · Drug: Bendamustine · Drug: Rituximab
Participants will receive rituximab 375 mg/m\^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m\^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
Drug: Bendamustine · Drug: Rituximab
Venetoclax will be administered as per the schedule specified under arm description.
Also known as: GDC-0199, ABT-199
Bendamustine will be administered as per the schedule specified under arm description.
Also known as: Levact
Rituximab will be administered as per the schedule specified under arm description.
Also known as: MabThera, Rituxan
Percentage of Participants With Complete Metabolic Response (CMR) According to Independent Review Committee (IRC) as Per Lugano Classification, Using Positron Emission Tomography (PET) Scan at Primary Response Assessment (PRA)
CMR: a score 1 (no uptake above background), 2 (uptake less than or equal to \[\<=\] mediastinum), or 3 (uptake less than \[\<\] mediastinum but \<=liver) with or without a residual mass on PET 5-point scale (5-PS), for lymph nodes and extralymphatic sites with no new lesions and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% confidence interval (CI) for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 6-8 weeks after Cycle 6 Day 1 (PRA) (Cycle length = 28 days)
Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at PRA
CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 4-10 weeks after Cycle 6 Day 1 (Cycle length = 28 days)
Percentage of Participants With CMR According to IRC as Per Lugano Classification, Using PET Scan at Year 1
CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (uptake \<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at Year 1
CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Percentage of Participants With Complete Response (CR) According to IRC as Per Lugano Classification, Using Computed Tomography (CT) Scan
CR: defined as reduction of longest transverse diameter of lesion (LDi) of target nodes/nodal masses to \<=1.5 centimeters (cm), and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/immunohistochemistry (IHC)-negative bone marrow morphology. Assessment was performed by an IRC according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 6-8 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Percentage of Participants With CR According to Investigator as Per Lugano Classification, Using CT Scan
CR: defined as reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. Assessment was performed by Investigator according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 4-10 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Percentage of Participants With Objective Response (OR) According to IRC as Per Lugano Classification, Using PET Scan
OR was defined as CMR or Partial Metabolic Response (PMR). CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. PMR: a score 4 (uptake moderately greater than \[\>\] liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites with no new lesions and reduced residual uptake in bone marrow compared with baseline. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 6-8 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET Scan
OR was defined as CMR or PMR. CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. PMR: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites with no new lesions and reduced residual uptake in bone marrow compared with baseline. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 4-10 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Percentage of Participants With OR According to IRC as Per Lugano Classification, Using CT Scan
OR was defined as CR or Partial Response (PR). CR: reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. PR: greater than or equal to (\>=) 50 percent (%) decrease in sum of the product of the perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen at least \>50% beyond normal; and no new lesions. Assessment was performed by an IRC according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 6-8 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using CT Scan
OR was defined as CR or PR. CR: reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. PR: \>=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen at least \>50% beyond normal; and no new lesions. Assessment was performed by Investigator according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
Time frame: 4-10 weeks after Cycle 6 Day 1 and 48-56 weeks after Cycle 1 Day 1 (Cycle length = 28 days)
Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET or CT Scan
OR was defined as CMR/CR or PMR/PR. CMR, CR, PMR, and PR have been defined in previous endpoints, and are not repeated here due to space constraint. Assessment was performed by Investigator according to Lugano classification using PET scan or CT scan (if PET is missing).
Time frame: Baseline until disease progression or death due to any cause (assessed up to approximately 2.5 years)
Duration of Response (DOR) According to Investigator as Per Lugano Classification, Using PET or CT Scan
DOR was defined as time from CMR/CR or PMR/PR until progressive disease (PD) or death due to any cause. CMR, CR, PMR, and PR have been defined in previous endpoints, and are not repeated here due to space constraint. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan or CT scan (if PET is missing). DOR was calculated using Kaplan-Meier method.
Time frame: From CMR or PMR until disease progression or death due to any cause (assessed up to approximately 2.5 years)
Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan) or Death
PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan.
Time frame: Baseline until disease progression or death due to any cause (assessed up to approximately 2.5 years)
Progression-Free Survival (PFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan
PFS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) until the date of disease progression, or death due to any cause. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan. PFS was calculated using Kaplan-Meier method.
Time frame: Baseline until disease progression or death due to any cause (assessed up to approximately 2.5 years)
Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan), Death, or Start of a New Anti-lymphoma Therapy
PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan.
Time frame: Baseline until disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first (assessed up to approximately 2.5 years)
Event-Free Survival (EFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan
EFS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) to the date of disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan. EFS was calculated using Kaplan-Meier method.
Time frame: Baseline until disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first (assessed up to approximately 2.5 years)
Percentage of Participants Who Died Due to Any Cause
Time frame: Baseline until death due to any cause (assessed up to approximately 2.5 years
Overall Survival (OS)
OS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) to death due to any cause. For participants who are alive, OS was censored at the last contact. OS was calculated using Kaplan-Meier method.
Time frame: Baseline until death due to any cause (assessed up to approximately 2.5 years)
Apparent Clearance (CL) of Venetoclax
CL is a quantitative measure of the rate at which a drug substance is removed from the body.
Time frame: Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Apparent Volume of Distribution (Vd) of Venetoclax
Vd was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Time frame: Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Time to Maximum Plasma Concentration (Tmax) of Venetoclax
Time frame: Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Maximum Plasma Concentration (Cmax) of Venetoclax
Time frame: Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Area Under the Plasma Concentration-Time Curve From Time 0 to Last Observed Concentration (AUClast) of Venetoclax
Area under the plasma concentration versus time curve from zero to the last measured concentration (AUClast).
Time frame: Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post Dose (AUC0-8h) of Venetoclax
Area under the plasma concentration versus time curve from time 0 (pre-dose) to 8 hours post dose (AUC0-8h).
Time frame: Pre-dose (within 30 minutes), and 2, 4, 6, 8 hours post-dose on Cycle 1 Day 1; pre-dose (within 30 minutes) on Cycle 1 Days 8, 15, 22; pre-dose (within 30 minutes) and 4 hours post-dose on Day 1 of Cycles 4 and 6 (Cycle length = 28 days)
| Milestone | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Started | 9 | 52 | 51 | 51 |
| Treated | 9 | 52 | 49 | 50 |
| Completed | 3 | 4 | 19 | 19 |
| Not completed | 6 | 48 | 32 | 32 |
| Withdrew: Adverse event | 2 | 1 | 2 | 1 |
| Withdrew: Death | 0 | 3 | 1 | 2 |
| Withdrew: Physician decision | 0 | 1 | 0 | 3 |
| Withdrew: Progressive disease | 4 | 42 | 19 | 22 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 3 |
| Withdrew: Other | 0 | 1 | 7 | 1 |
CMR: a score 1 (no uptake above background), 2 (uptake less than or equal to \[\<=\] mediastinum), or 3 (uptake less than \[\<\] mediastinum but \<=liver) with or without a residual mass on PET 5-point scale (5-PS), for lymph nodes and extralymphatic sites with no new lesions and no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% confidence interval (CI) for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Percentage of Participants With Complete Metabolic Response (CMR) According to Independent Review Committee (IRC) as Per Lugano Classification, Using Positron Emission Tomography (PET) Scan at Primary Response Assessment (PRA) | 55.6 (21.20 to 86.30) | 11.5 (4.35 to 23.44) | 74.5 (60.37 to 85.67) | 70.6 (56.17 to 82.51) |
CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at PRA | 55.6 (21.20 to 86.30) | 15.4 (6.88 to 28.08) | 70.6 (56.17 to 82.51) | 68.6 (54.11 to 80.89) |
CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (uptake \<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Percentage of Participants With CMR According to IRC as Per Lugano Classification, Using PET Scan at Year 1 | 55.6 (21.20 to 86.30) | 21.2 (11.06 to 34.70) | 41.2 (27.58 to 55.83) | 39.2 (25.84 to 53.89) |
CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at Year 1 | 55.6 (21.20 to 86.30) | 17.3 (8.23 to 30.33) | 39.2 (25.84 to 53.89) | 47.1 (32.93 to 61.54) |
CR: defined as reduction of longest transverse diameter of lesion (LDi) of target nodes/nodal masses to \<=1.5 centimeters (cm), and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/immunohistochemistry (IHC)-negative bone marrow morphology. Assessment was performed by an IRC according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| 6-8 weeks after Cycle 6 Day 1 | 44.4 (13.70 to 78.80) | 5.7 (1.18 to 15.66) | 39.2 (25.84 to 53.89) | 25.5 (14.33 to 39.63) |
| Year 1 | 55.6 (21.20 to 86.30) | 13.2 (5.48 to 25.34) | 27.5 (15.89 to 41.74) | 23.5 (12.79 to 37.49) |
CR: defined as reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. Assessment was performed by Investigator according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| 4-10 weeks after Cycle 6 Day 1 | 22.2 (2.81 to 60.01) | 5.7 (1.18 to 15.66) | 15.7 (7.02 to 28.59) | 31.4 (19.11 to 45.89) |
| Year 1 | 33.3 (7.49 to 70.07) | 5.7 (1.18 to 15.66) | 13.7 (5.70 to 26.26) | 21.6 (11.29 to 35.32) |
OR was defined as CMR or Partial Metabolic Response (PMR). CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. PMR: a score 4 (uptake moderately greater than \[\>\] liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites with no new lesions and reduced residual uptake in bone marrow compared with baseline. Assessment was performed by an IRC according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| 6-8 weeks after Cycle 6 Day 1 | 55.6 (21.20 to 86.30) | 21.2 (11.06 to 34.70) | 76.5 (62.51 to 87.21) | 74.5 (60.37 to 85.67) |
| Year 1 | 66.7 (29.93 to 92.51) | 32.7 (20.33 to 47.11) | 45.1 (31.13 to 59.66) | 51.0 (36.60 to 65.25) |
OR was defined as CMR or PMR. CMR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. PMR: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites with no new lesions and reduced residual uptake in bone marrow compared with baseline. Assessment was performed by Investigator according to Lugano classification using PET scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| 4-10 weeks after Cycle 6 Day 1 | 55.6 (21.20 to 86.30) | 28.8 (17.13 to 43.08) | 76.5 (62.51 to 87.21) | 76.5 (62.51 to 87.21) |
| Year 1 | 55.6 (21.20 to 86.30) | 21.2 (11.06 to 34.70) | 39.2 (25.84 to 53.89) | 49.0 (34.75 to 63.40) |
OR was defined as CR or Partial Response (PR). CR: reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. PR: greater than or equal to (\>=) 50 percent (%) decrease in sum of the product of the perpendicular diameters (SPD) of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen at least \>50% beyond normal; and no new lesions. Assessment was performed by an IRC according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| 6-8 weeks after Cycle 6 Day 1 | 66.7 (29.93 to 92.51) | 30.2 (18.34 to 44.34) | 80.4 (66.88 to 90.18) | 84.3 (71.41 to 92.98) |
| Year 1 | 66.7 (29.93 to 92.51) | 22.6 (12.28 to 36.21) | 41.2 (27.58 to 55.83) | 60.8 (46.11 to 74.16) |
OR was defined as CR or PR. CR: reduction of LDi of target nodes/nodal masses to \<=1.5 cm, and no extralymphatic sites of disease; absence of non-measured lesions and new lesions; reduction of enlarged organs to normal; and normal/IHC-negative bone marrow morphology. PR: \>=50% decrease in SPD of up to 6 target measurable nodes and extra-nodal sites; absence/reduction/no increase in size of non-measured lesions; reduction in length of spleen at least \>50% beyond normal; and no new lesions. Assessment was performed by Investigator according to Lugano classification using CT scan. 95% CI for percentage of responders was calculated using Clopper-Pearson method.
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| 4-10 weeks after Cycle 6 Day 1 | 55.6 (21.20 to 86.30) | 32.1 (19.92 to 46.32) | 74.5 (60.37 to 85.67) | 78.4 (64.68 to 88.71) |
| Year 1 | 55.6 (21.20 to 86.30) | 28.3 (16.79 to 42.35) | 47.1 (32.93 to 61.54) | 49.0 (34.75 to 63.40) |
OR was defined as CMR/CR or PMR/PR. CMR, CR, PMR, and PR have been defined in previous endpoints, and are not repeated here due to space constraint. Assessment was performed by Investigator according to Lugano classification using PET scan or CT scan (if PET is missing).
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET or CT Scan | 66.7 (29.93 to 92.51) | 36.5 (23.62 to 51.04) | 80.4 (66.88 to 90.18) | 80.4 (66.88 to 90.18) |
DOR was defined as time from CMR/CR or PMR/PR until progressive disease (PD) or death due to any cause. CMR, CR, PMR, and PR have been defined in previous endpoints, and are not repeated here due to space constraint. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET scan or CT scan (if PET is missing). DOR was calculated using Kaplan-Meier method.
| months | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Duration of Response (DOR) According to Investigator as Per Lugano Classification, Using PET or CT Scan | 32.46 (9.46 to 32.46) | 15.79 (10.15 to 23.49) | 24.87 (12.45 to NA) | 15.64 (12.09 to NA) |
PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan.
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan) or Death | 44.4 | 86.5 | 41.2 | 52.9 |
PFS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) until the date of disease progression, or death due to any cause. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan. PFS was calculated using Kaplan-Meier method.
| months | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Progression-Free Survival (PFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan | 35.09 (12.78 to 35.09) | 6.57 (6.18 to 12.25) | 27.63 (16.07 to NA) | 18.43 (16.92 to NA) |
PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan.
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan), Death, or Start of a New Anti-lymphoma Therapy | 44.4 | 86.5 | 41.2 | 52.9 |
EFS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) to the date of disease progression, death, or start of a new anti-lymphoma therapy whichever occurred first. PD: a score 4 (uptake moderately \>liver) or 5 (uptake markedly \>liver and/or new lesions) with increase in intensity of uptake from baseline on PET 5-PS for individual target nodes/nodal lesions; new FDG-avid foci for extranodal lesions; new FDG-avid foci consistent with lymphoma for new lesions; or new or recurrent FDG-avid foci for bone marrow. Assessment was performed by Investigator according to Lugano classification using PET or CT scan. EFS was calculated using Kaplan-Meier method.
| months | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Event-Free Survival (EFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan | 35.09 (12.78 to 35.09) | 6.57 (6.18 to 12.25) | 27.63 (16.07 to NA) | 18.43 (16.92 to NA) |
| percentage of participants | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Percentage of Participants Who Died Due to Any Cause | 0 | 5.8 | 2.0 | 3.9 |
OS was defined as the period from the date of treatment initiation (Safety Run-in and Arm A) or randomization date (Arms B and C) to death due to any cause. For participants who are alive, OS was censored at the last contact. OS was calculated using Kaplan-Meier method.
| months | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
CL is a quantitative measure of the rate at which a drug substance is removed from the body.
No measurements were reported for this outcome.
Vd was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
No measurements were reported for this outcome.
| hours | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) |
|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Venetoclax | 8.00 (4.00 to 8.08) | 6.00 (1.95 to 8.18) | 6.21 (1.98 to 9.22) |
| nanograms per milliliter (ng/mL) | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Venetoclax | 1350 ± 427 | 1220 ± 478 | 1340 ± 460 |
Area under the plasma concentration versus time curve from zero to the last measured concentration (AUClast).
| hours*ng/mL | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 0 to Last Observed Concentration (AUClast) of Venetoclax | 5310 ± 1730 | 4950 ± 1950 | 5500 ± 2270 |
Area under the plasma concentration versus time curve from time 0 (pre-dose) to 8 hours post dose (AUC0-8h).
| hours*ng/mL | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post Dose (AUC0-8h) of Venetoclax | 5240 ± 1860 | 4820 ± 1980 | 5330 ± 2270 |
Collected over Baseline up to approximately 2.5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | — | 4/9 (44.4%) | 9/9 (100%) |
| Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | — | 16/52 (30.8%) | 49/52 (94.2%) |
| Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | — | 26/49 (53.1%) | 49/49 (100%) |
| Chemotherapy-Containing Cohort: Arm C (BR) | — | 12/50 (24%) | 48/50 (96%) |
| Event | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/9 | 0/52 | 6/49 | 3/50 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/9 | 0/52 | 1/49 | 0/50 |
| Cardiac failureCardiac disorders | 1/9 | 0/52 | 0/49 | 0/50 |
| PyrexiaGeneral disorders | 1/9 | 0/52 | 0/49 | 0/50 |
| Acute sinusitisInfections and infestations | 1/9 | 0/52 | 0/49 | 0/50 |
| Clostridium difficile colitisInfections and infestations | 1/9 | 0/52 | 0/49 | 0/50 |
| Myelodysplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/9 | 0/52 | 3/49 | 0/50 |
| SyncopeNervous system disorders | 1/9 | 0/52 | 1/49 | 1/50 |
| NEUTROPENIABlood and lymphatic system disorders | 1/9 | 0/52 | 1/49 | 0/50 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/9 | 0/52 | 3/49 | 0/50 |
| Event | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 7/9 | 14/52 | 32/49 | 23/50 |
| NeutropeniaBlood and lymphatic system disorders | 5/9 | 14/52 | 30/49 | 17/50 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/9 | 7/52 | 28/49 | 8/50 |
| DiarrhoeaGastrointestinal disorders | 5/9 | 21/52 | 24/49 | 14/50 |
| VomitingGastrointestinal disorders | 4/9 | 7/52 | 23/49 | 13/50 |
| FatigueGeneral disorders | 3/9 | 13/52 | 21/49 | 15/50 |
| AnaemiaBlood and lymphatic system disorders | 2/9 | 3/52 | 19/49 | 8/50 |
| Infusion related reactionInjury, poisoning and procedural complications | 2/9 | 18/52 | 10/49 | 7/50 |
| ConstipationGastrointestinal disorders | 3/9 | 5/52 | 10/49 | 17/50 |
| NasopharyngitisInfections and infestations | 3/9 | 4/52 | 1/49 | 0/50 |
Intent-to-treat (ITT) population included all enrolled participants.
| Age, Continuous(years) | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) | Total |
|---|---|---|---|---|---|
| Mean | 57.9 ± 12.7 | 61.9 ± 12.0 | 64.9 ± 9.8 | 61.0 ± 11.6 | 62.3 ± 11.3 |
| Sex: Female, Male(Participants) | Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR) | Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab) | Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR) | Chemotherapy-Containing Cohort: Arm C (BR) | Total |
|---|---|---|---|---|---|
| Female | 5 | 25 | 16 | 21 | 67 |
| Male | 4 | 27 | 35 | 30 | 96 |
Ran from Dec 2014 to primary completion in Sep 2016, 21 months.
Results were first posted in Oct 2017, 1 year after primary completion.
Of 48 industry-sponsored phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's 21 months is below that.
Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Venetoclax · Bendamustine